177Lu‐[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy

177Lu‐(DOTA0,Tyr3) octreotate is a new treatment modality for disseminated neuroendocrine tumors. According to a consensus protocol, the calculated maximally tolerated absorbed dose to the kidney should not exceed 27 Gy. In commonly used dosimetry methods, planar imaging is used for determination of the residence time, whereas the kidney mass is determined from a computed tomography (CT) scan.

[1]  Marion de Jong,et al.  Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  J. Valentin.  Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[4]  L. Kvols,et al.  Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. , 2002, Seminars in nuclear medicine.

[5]  Michael Ljungberg,et al.  The LundADose method for planar image activity quantification and absorbed-dose assessment in radionuclide therapy. , 2005, Cancer biotherapy & radiopharmaceuticals.

[6]  B. Tsui,et al.  A new method for modeling the spatially-variant, object-dependent scatter response function in SPECT , 1996, 1996 IEEE Nuclear Science Symposium. Conference Record.

[7]  Giovanni Paganelli,et al.  Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  E. Krenning,et al.  [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients , 2001, European Journal of Nuclear Medicine.

[9]  Basic anatomical and physiological data for use in radiological protection: the skeleton. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection. , 1995, Annals of the ICRP.

[10]  K Erlandsson,et al.  Registration of emission and transmission whole-body scintillation-camera images. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Michael Ljungberg,et al.  An activity quantification method based on registration of CT and whole-body scintillation camera images, with application to 131I. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  R. Valkema,et al.  Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  J. Cassady,et al.  Clinical radiation nephropathy. , 1995, International journal of radiation oncology, biology, physics.

[14]  Marion de Jong,et al.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  E P Krenning,et al.  [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. , 2001, European journal of nuclear medicine.

[16]  E. Krenning,et al.  Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Michael Ljungberg,et al.  A new method to obtain transmission images for planar whole-body activity quantification. , 2005, Cancer biotherapy & radiopharmaceuticals.

[18]  M. Ljungberg,et al.  A Monte Carlo program for the simulation of scintillation camera characteristics. , 1989, Computer methods and programs in biomedicine.

[19]  J. H. Hubbell,et al.  XCOM: Photon cross sections on a personal computer , 1987 .

[20]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[21]  R. Dale,et al.  The radiobiology of conventional radiotherapy and its application to radionuclide therapy. , 2005, Cancer biotherapy & radiopharmaceuticals.